siRNA silencing of calumenin enhances functional factor IX production

Blood

Volumn 108, Issue 12, 2006, Pages 3757-3760

  Wajih, Nadeem ^a   Hutson, Susan M ^a   Wallin, Reidar ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALUMENIN; ENZYME INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 9; SMALL INTERFERING RNA; VITAMIN K DEPENDENT CARBOXYLASE;

ANIMAL CELL; ARTICLE; BIOENGINEERING; BLOOD CLOTTING; CARBOXYLATION; CONTROLLED STUDY; GENE SILENCING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS;

EID: 33845249178     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-02-004671     Document Type: Article

References (21)

1. Furie B, Furie BC. The molecular basis of blood coagulation. Cell. 1988;53:505-518.
2. Forastiero RR, Martinuzzo ME, Lu J, Broze J. Autoimmune antiphospholipid antibodies impair the inhibition of activated factor X by protein Z/protein Z-dependent protease inhibitor. J Thromb Haemost. 2003;1:1764-1770.
3. Hedner U. Recombinant factor VIIa (Novoseven) as a hemostatic agent. Semin Hematol. 2001;38(suppl 12):43-47.
4. Roth DA, Kessler CM, Pasi J, Rup B, Courter SG, Tubridy KL. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood. 2001;98:3600-3606.
5. Bernard GR, Vincent J-L, Laterre P-F, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
6. Kaufman RJ, Wasley LC, Furie BC, Furie B, Shoemaker CB. Expression, purification, and characterization of recombinant gamma-carboxylated factor IX synthesized in Chinese hamster ovary cells. J Biol Chem. 1986;261:9622-9628.
7. Li T, Chang C-Y, Jin D-Y, Lin P-J, Khvorova A, Stafford D. Identification of the gene for vitamin K epoxide reductase. Nature. 2004;427:541-544.
8. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004;427:537-541.
9. Rehemtulla A, Roth DA, Wasley LC, et al. In vitro and in vivo functional characterization of bovine vitamin K-dependent gamma-carboxylase expressed in Chinese hamster ovary cells. Proc Natl Acad Sci U S A. 1993;90:4611-4615.
10. Wajih N, Hutson SM, Owen J, Wallin R. Increased production of functional recombinant human clotting factor IX by baby hamster kidney cells engineered to overexpress VKORC1, the vitamin K 2,3-epoxide-reducing enzyme of the vitamin K cycle. J Biol Chem. 2005;280:31603-31607.
11. Goodstadt L, Ponting CP. Vitamin K epoxide reductase: homology, active site and catalytic mechanism. Trends Biochem Sci. 2004;29:289-292.
12. Wallin R, Hutson SM, Cain D, Sweatt A, Sane DC. A molecular mechanism for genetic warfarin resistance in the rat. FASEB J. 2001;15:2542-2544.
13. Wallin R, Hutson SM. Warfarin and the vitamin K-dependent gamma-carboxylation system. Trends Mol Med. 2004;10:299-302.
14. Wallin R, Sane DC, Hutson SM. Vitamin K 2,3-epoxide reductase and the vitamin K-dependent gamma-carboxylation system. Thromb Res. 2002;108:221-226.
15. Sun YM, Jin DY, Camire RM, Stafford DW. Vitamin K epoxide reductase significantly improves carboxylation in a cell line overexpressing factor X. Blood. 2005;106:3811-3815.
16. Hallgren KW, Qian W, Yakubenko AV, Ruge KV, Berkner KL. R-VKORC1 expression in factor IX BHK cells increases the extent of factor IX carboxylation but is limited by saturation of another carboxylation component or by a shift in the rate-limiting step. Biochemistry. 2006;45:5587-5598.
17. Wajih N, Sane DC, Hutson SM, Wallin R. The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system: characterization of the system in normal and warfarin-resistant rats. J Biol Chem. 2004;279:25276-25283.
18. Wajih N, Sane DC, Hutson SM, Wallin RJ. Engineering of a recombinant vitamin K-dependent gamma-carboxylation system with enhanced gamma-carboxyglutamic acid forming capacity: evidence for a functional CXXC redox center in the system. J Biol Chem. 2005;280:10540-10547.
19. Wallin R, Martin LF. Vitamin K-dependent carboxylation and vitamin K metabolism in liver: effects of warfarin. J Clin Invest. 1985;76:1879-1884.
20. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med. 1992;326:800-806.
21. 2+ -binding proteins localized to the secretory pathway of mammalian cells. FEBS Lett. 2000;466:11-18.